Logo Logo
Eine Ebene nach oben
Exportieren als [RSS feed] RSS 1.0 [RSS2 feed] RSS 2.0
Gruppiert nach: Dokumententyp | Veröffentlichungsdatum
Anzahl der Publikationen: 7

Zeitschriftenartikel

Feder, K.; Edmaier, K.; Eshraghi, P.; Vegi, N.; Mulaw, M.; Ihme, S.; Spiekermann, K.; Metzeler, K.; Hiddemann, W.; Döhner, K.; Döhner, H.; Feuring-Buske, M. und Buske, C. (2016): The Lef1 isoform, lacking the β-catenin binding domain, is not acting as a dominant negative Lef1 variant, but is a hematopoietic active protein with unique DNA binding properties. In: Oncology Research and Treatment, Bd. 39: S. 46

Schneider, F.; Hoster, Eva; Schneider, S.; Dufour, A.; Benthaus, T.; Kakadia, P. M.; Bohlander, Stefan K.; Braess, J.; Heinecke, A.; Sauerland, M. C.; Berdel, W. E.; Büchner, T.; Wörmann, Bernhard; Feuring-Buske, M.; Buske, C.; Creutzig, U.; Thiede, C.; Zwaan, M. C.; Heuvel-Eibrink, M. M. van den; Reinhardt, D.; Hiddemann, Wolfgang und Spiekermann, Karsten (2012): Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). In: Annals of Hematology, Bd. 91, Nr. 1: S. 9-18

Schneider, F.; Hoster, Eva; Unterhalt, Michael; Schneider, S.; Dufour, A.; Benthaus, T.; Mellert, G.; Zellmeier, Evelyn; Kakadia, P. M.; Bohlander, Stefan K.; Feuring-Buske, M.; Buske, C.; Braess, J.; Heinecke, A.; Sauerland, M. C.; Berdel, W. E.; Büchner, T.; Wörmann, Bernhard; Hiddemann, Wolfgang und Spiekermann, Karsten (2012): The FLT3ITD level has a high prognostic impact in NPM1 mutated, but not NPM1 unmutated AML with a normal karyotype. In: Blood, Bd. 119, Nr. 19: S. 4383-4386

Herold, Tobias; Jurinovic, Vindi; Metzeler, Klaus H.; Boulesteix, Anne-Laure; Bergmann, M.; Seiler, T.; Mulaw, M.; Thoene, S.; Dufour, A.; Pasalic, Z.; Schmidberger, Markus; Schmidt, M.; Schneider, S.; Kakadia, P. M.; Feuring-Buske, M.; Braess, J.; Spiekermann, Karsten; Mansmann, Ulrich; Hiddemann, Wolfgang; Buske, C. und Bohlander, Stefan K. (2011): An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. In: Leukemia, Bd. 25, Nr. 10: S. 1639-1645

Herold, Tobias; Jurinovic, Vindi; Mulaw, M.; Seiler, T.; Dufour, A.; Schneider, S.; Kakadia, P. M.; Feuring-Buske, M.; Braess, J.; Spiekermann, Karsten; Mansmann, Ulrich; Hiddemann, Wolfgang; Buske, C. und Bohlander, Stefan K. (2011): Expression analysis of genes located in the minimally deleted regions of 13q14 and 11q22-23 in chronic lymphocytic leukemia-unexpected expression pattern of the RHO GTPase activator ARHGAP20. In: Genes, Chromosomes and Cancer, Bd. 50, Nr. 7: S. 546-558

Thoene, S.; Rawat, V. P.; Heilmeier, B.; Hoster, Eva; Metzeler, Klaus H.; Herold, Tobias; Hiddemann, Wolfgang; Gökbuget, Nicola; Hoelzer, D.; Bohlander, Stefan K.; Feuring-Buske, M. und Buske, C. (2009): The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia. In: Leukemia, Bd. 23, Nr. 4: S. 649-655

Schneider, F.; Hoster, Eva; Unterhalt, Michael; Schneider, S.; Dufour, A.; Benthaus, T.; Mellert, G.; Zellmeier, Evelyn; Bohlander, Stefan K.; Feuring-Buske, M.; Buske, C.; Braess, J.; Fritsch, S.; Heinecke, A.; Sauerland, M. C.; Berdel, W. E.; Büchner, T.; Wörmann, Bernhard; Hiddemann, Wolfgang und Spiekermann, Karsten (2009): NPM1, but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high risk myelodysplastic syndrome (MDS). In: Blood, Bd. 113, Nr. 21: S. 5250-5253

Diese Liste wurde am Sat Apr 13 20:58:44 2024 CEST erstellt.